Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.

Dignass AU, Siegmund B, Goertz R, Schneidewind G, Fanter L.

Scand J Gastroenterol. 2019 Feb;54(2):178-187. doi: 10.1080/00365521.2019.1569124. Epub 2019 Feb 8.

PMID:
30735443
2.

European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease.

Rieder F, Latella G, Magro F, Yuksel ES, Higgins PD, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d'Hoore A, Pellino G, Dignass AU.

J Crohns Colitis. 2016 Aug;10(8):873-85. doi: 10.1093/ecco-jcc/jjw055. Epub 2016 Feb 29.

PMID:
26928961
3.

Anaemia in the Elderly IBD Patient.

Stein J, Dignass AU.

Curr Treat Options Gastroenterol. 2015 Sep;13(3):308-18. doi: 10.1007/s11938-015-0062-y.

PMID:
26164616
4.

[Current position on Vedolizumab for ulcerative colitis and Crohn's disease].

Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.

Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27. Review. German.

5.

European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.

Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, Gomollon F, Iqbal T, Katsanos K, Koutroubakis I, Magro F, Savoye G, Stein J, Vavricka S; European Crohn’s and Colitis Organisation [ECCO].

J Crohns Colitis. 2015 Mar;9(3):211-22. doi: 10.1093/ecco-jcc/jju009. Epub 2014 Dec 3. No abstract available.

PMID:
25518052
6.

Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation.

Fürnkranz A, Bordignon S, Böhmig M, Konstantinou A, Dugo D, Perrotta L, Klopffleisch T, Nowak B, Dignaß AU, Schmidt B, Chun JK.

Heart Rhythm. 2015 Feb;12(2):268-74. doi: 10.1016/j.hrthm.2014.10.033. Epub 2014 Nov 4.

PMID:
25446159
7.

Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.

Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P.

J Crohns Colitis. 2014 Mar;8(3):200-7. doi: 10.1016/j.crohns.2013.08.007. Epub 2013 Sep 4.

8.

Luminal esophageal temperature predicts esophageal lesions after second-generation cryoballoon pulmonary vein isolation.

Fürnkranz A, Bordignon S, Schmidt B, Böhmig M, Böhmer MC, Bode F, Schulte-Hahn B, Nowak B, Dignaß AU, Chun JK.

Heart Rhythm. 2013 Jun;10(6):789-93. doi: 10.1016/j.hrthm.2013.02.021. Epub 2013 Feb 19.

PMID:
23428962
9.

Management of iron deficiency anemia in inflammatory bowel disease - a practical approach.

Stein J, Dignass AU.

Ann Gastroenterol. 2013;26(2):104-113. Review.

10.

[Alcoholic hepatitis - are the administration of N-acetylcystein in combination with glucocorticoids or early liver transplantation helpful therapeutic options?].

Thieringer J, Dignass AU.

Z Gastroenterol. 2012 Jul;50(7):699-701. doi: 10.1055/s-0031-1299511. Epub 2012 Jul 3. German. No abstract available.

PMID:
22760683
11.

[Rational and efficient diagnosis in different stages of Crohn's disease].

Teich N, Helwig U, Pace A, Dignass AU, Hartmann F, Hüppe D, Schmidt C, Stallmach A, Sturm A, Kruis W, Layer P.

Z Gastroenterol. 2012 Jul;50(7):684-93. doi: 10.1055/s-0031-1299461. Epub 2012 Jul 3. Review. German.

PMID:
22760681
12.

Selective non-steroidal glucocorticoid receptor agonists attenuate inflammation but do not impair intestinal epithelial cell restitution in vitro.

Reuter KC, Loitsch SM, Dignass AU, Steinhilber D, Stein J.

PLoS One. 2012;7(1):e29756. doi: 10.1371/journal.pone.0029756. Epub 2012 Jan 25.

13.

Interferon-γ modulates intestinal epithelial cell function in-vitro through a TGFβ-dependent mechanism.

Hoffmann P, Sturm A, Stein J, Dignass AU.

Regul Pept. 2011 Jun 7;168(1-3):27-31. doi: 10.1016/j.regpep.2011.02.013. Epub 2011 Mar 5.

PMID:
21385594
14.

Diagnosis and management of iron deficiency anemia in patients with IBD.

Stein J, Hartmann F, Dignass AU.

Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):599-610. doi: 10.1038/nrgastro.2010.151. Epub 2010 Oct 5. Review.

PMID:
20924367
15.

Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis.

Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S.

Aliment Pharmacol Ther. 2010 Jun;31(12):1286-95. doi: 10.1111/j.1365-2036.2010.04295.x. Epub 2010 Mar 11.

16.

[Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial].

Blumenstein I, Bock H, Zosel C, Dignass AU, Hartmann F, Zeuzem S, Stein JM, Schroeder O.

Z Gastroenterol. 2009 Oct;47(10):1045-51. doi: 10.1055/s-0028-1109647. Epub 2009 Oct 6. German.

PMID:
19809954
17.

Management of inflammatory bowel diseases during pregnancy.

Dignass AU, Hartmann F, Sturm A, Stein J.

Dig Dis. 2009;27(3):341-6. doi: 10.1159/000228571. Epub 2009 Sep 24. Review.

PMID:
19786762
18.

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ.

Inflamm Bowel Dis. 2010 Apr;16(4):620-9. doi: 10.1002/ibd.21084.

PMID:
19714757
19.

Galectin-2 suppresses contact allergy by inducing apoptosis in activated CD8+ T cells.

Loser K, Sturm A, Voskort M, Kupas V, Balkow S, Auriemma M, Sternemann C, Dignass AU, Luger TA, Beissert S.

J Immunol. 2009 May 1;182(9):5419-29. doi: 10.4049/jimmunol.0802308.

20.

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.

Clin Gastroenterol Hepatol. 2009 Jul;7(7):762-9. doi: 10.1016/j.cgh.2009.04.004. Epub 2009 Apr 16.

PMID:
19375519
21.

[Pathophysiological-based diagnosis and therapy of iron-deficient anaemia in inflammatory bowel disease].

Stein JM, Hartmann F, Cordes HJ, Dignass AU.

Z Gastroenterol. 2009 Feb;47(2):228-36. doi: 10.1055/s-2008-1027876. Epub 2009 Feb 5. Review. German.

PMID:
19197827
22.

Galectin-2 and -4, but not galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism.

Paclik D, Lohse K, Wiedenmann B, Dignass AU, Sturm A.

Inflamm Bowel Dis. 2008 Oct;14(10):1366-72. doi: 10.1002/ibd.20499.

PMID:
18484670
23.

Epithelial restitution and wound healing in inflammatory bowel disease.

Sturm A, Dignass AU.

World J Gastroenterol. 2008 Jan 21;14(3):348-53. Review.

24.

Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice.

Paclik D, Berndt U, Guzy C, Dankof A, Danese S, Holzloehner P, Rosewicz S, Wiedenmann B, Wittig BM, Dignass AU, Sturm A.

J Mol Med (Berl). 2008 Dec;86(12):1395-406. Epub 2007 Dec 7.

PMID:
18064431
25.

Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis.

Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hämmerle M, Sturm A.

J Immunol. 2007 Jul 1;179(1):295-304.

26.

Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A.

Infect Immun. 2006 Jul;74(7):4075-82.

27.

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.

Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU.

Am J Gastroenterol. 2006 May;101(5):1048-56.

PMID:
16573777
28.

Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.

Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.

Am J Gastroenterol. 2005 Nov;100(11):2503-9.

PMID:
16279906
29.

[Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy?].

Baumgart DC, Dignass AU.

Z Gastroenterol. 2003 May;41(5):478-9. German. No abstract available.

PMID:
16279009
30.

Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism.

Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU.

Scand J Gastroenterol. 2005 Aug;40(8):958-64.

PMID:
16165710
31.

[Management of perianal fistulizing Crohn's disease: a conservative approach].

Dignass AU.

Dtsch Med Wochenschr. 2005 Aug 26;130(34-35):1968. German. No abstract available.

PMID:
16123902
32.

Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis.

Baumgart DC, Sturm A, Wiedenmann B, Dignass AU.

Gut. 2005 Dec;54(12):1822-3. Epub 2005 Aug 24. No abstract available.

33.

Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.

Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U, Wiedenmann B, Dignass AU.

Infect Immun. 2005 Mar;73(3):1452-65.

34.

Postprandial abdominal pain, megaloblastic anaemia, and severe weight loss in an 80 year old man.

Dignass AU, Pascu ME, Roznowski AB, Wiedenmann B.

Gut. 2005 Mar;54(3):418, 436. No abstract available.

35.

Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells.

Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU.

Gut. 2005 Feb;54(2):228-36.

36.

CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway.

Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU.

Cytokine. 2005 Jan 7;29(1):42-8.

PMID:
15579377
37.

Current biological therapies for inflammatory bowel disease.

Baumgart DC, Dignass AU.

Curr Pharm Des. 2004;10(32):4127-47. Review.

PMID:
15579093
38.

Complication of Waldenstroem's macroglobulinaemia following ERCP.

Pascu M, Hanke B, Wiedenmann B, Martens F, Dignass AU.

Gut. 2004 Dec;53(12):1793; quiz answer 1812. No abstract available.

39.
40.

Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel.

Pascu M, Roznowski AB, Müller HP, Adler A, Wiedenmann B, Dignass AU.

Inflamm Bowel Dis. 2004 Jul;10(4):373-82.

PMID:
15475745
41.

[Ulcerative colitis. Chronic active course].

Dignass AU, Herrlinger K, Schölmerich J.

Z Gastroenterol. 2004 Sep;42(9):1006-10. German. No abstract available.

PMID:
15455274
42.

Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation.

Sturm A, Lensch M, André S, Kaltner H, Wiedenmann B, Rosewicz S, Dignass AU, Gabius HJ.

J Immunol. 2004 Sep 15;173(6):3825-37.

43.

Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.

Dignass AU, Baumgart DC, Sturm A.

Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:9-17. Review.

44.

A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.

Schröder O, Schrott M, Blumenstein I, Jahnel J, Dignass AU, Stein J.

Z Gastroenterol. 2004 Aug;42(8):663-7.

PMID:
15314711
45.

[Biologic therapy of inflammatory bowel disease].

Baumgart DC, Wiedenmann B, Dignass AU.

Z Gastroenterol. 2003 Oct;41(10):1017-32. Review. German.

PMID:
14562200
46.

Rescue therapy with tacrolimus in a patient with toxic megacolon.

Pascu M, Müller AR, Wiedenmann B, Dignass AU.

Int J Colorectal Dis. 2003 May;18(3):271-5.

PMID:
12785330
47.

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease.

Baumgart DC, Wiedenmann B, Dignass AU.

Aliment Pharmacol Ther. 2003 May 15;17(10):1273-81.

48.

Intestinal barrier function.

Baumgart DC, Dignass AU.

Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):685-94. Review.

PMID:
12394645
49.

Lisofylline and lysophospholipids ameliorate experimental colitis in rats.

Sturm A, Zeeh J, Sudermann T, Rath H, Gerken G, Dignass AU.

Digestion. 2002;66(1):23-9.

PMID:
12379812
50.

Functional relevance of activin A in the intestinal epithelium.

Dignass AU, Jung S, Harder-d'Heureuse J, Wiedenmann B.

Scand J Gastroenterol. 2002 Aug;37(8):936-43.

PMID:
12229969

Supplemental Content

Loading ...
Support Center